Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. (2022)
Attributed to:
A Dose Reduction Immunobridging Study of two HPV vaccines in Tanzanian girls
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2214-109x(22)00309-6
PubMed Identifier: 36113531
Publication URI: http://europepmc.org/abstract/MED/36113531
Type: Journal Article/Review
Volume: 10
Parent Publication: The Lancet. Global health
Issue: 10
ISSN: 2214-109X